These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]. Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550 [TBL] [Abstract][Full Text] [Related]
25. Targeted cancer therapy: from bench to bedside to patient. Gellad WF J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939 [No Abstract] [Full Text] [Related]
26. [Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET]. Kizaki M; Rinsho Ketsueki; 2007 Jun; 48(6):468-74. PubMed ID: 17633094 [No Abstract] [Full Text] [Related]
27. CML: imatinib mesylate (Glivec) or something else? Ghosh A Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026 [No Abstract] [Full Text] [Related]
28. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667 [TBL] [Abstract][Full Text] [Related]
30. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Marcucci G; Perrotti D; Caligiuri MA Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391 [No Abstract] [Full Text] [Related]
31. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431 [TBL] [Abstract][Full Text] [Related]
32. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833 [TBL] [Abstract][Full Text] [Related]
33. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244 [TBL] [Abstract][Full Text] [Related]
34. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation]. Fujisawa S; Yano K; Kobayashi M Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406 [TBL] [Abstract][Full Text] [Related]
35. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related]
36. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]. Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775 [TBL] [Abstract][Full Text] [Related]
37. A cancer 'smart bomb'. A new drug shows hope of conquering a form of leukemia by targeting the misbehaving cells. Kalb C Newsweek; 2000 Dec; 136(25):68. PubMed ID: 11126146 [No Abstract] [Full Text] [Related]
38. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Wodarz D Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666 [TBL] [Abstract][Full Text] [Related]
39. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370 [No Abstract] [Full Text] [Related]
40. Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program. Ladner J; Tekinturhan E; Tavolacci MP; Audureau E; Saba J J Health Care Poor Underserved; 2013 Nov; 24(4):1486-97. PubMed ID: 24185146 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]